PRDM16 regulates smooth muscle cell identity and atherosclerotic plaque composition

Area of Science:

• Cardiovascular Biology
• Cellular Biology
• Molecular Genetics

Background:

• Vascular smooth muscle cells (SMCs) switch phenotypes during pathological conditions like atherosclerosis.
• The 'synthetic' SMC phenotype, characterized by migration, proliferation, and matrix production, contributes to atherosclerotic lesion development.
• Mechanisms regulating the synthetic SMC phenotype are not fully understood.

Purpose of the Study:

• To identify key regulators of the synthetic vascular smooth muscle cell phenotype.
• To investigate the role of PRDM16 in SMC phenotype switching and atherosclerotic plaque formation.

Main Methods:

• Gene expression analysis in vascular smooth muscle cells.
• Genetic manipulation of PRDM16 in mouse models.
• Assessment of atherosclerotic plaque characteristics in vivo.
• Chromatin immunoprecipitation assays to determine PRDM16 binding sites.

Main Results:

• PRDM16 acts as a transcriptional repressor of the synthetic SMC phenotype.
• PRDM16 expression decreases during SMC modulation.
• PRDM16 deficiency promotes a synthetic SMC program, increasing fibroproliferative plaques and reducing foam cells in atherosclerosis.
• Overexpression of PRDM16 inhibits SMC migration, proliferation, and fibrosis.

Conclusions:

• PRDM16 is a critical gatekeeper of vascular smooth muscle cell fate.
• PRDM16 plays a significant role in regulating atherosclerotic plaque composition by controlling SMC phenotype.
• Targeting PRDM16 may offer therapeutic strategies for cardiovascular disease.